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Abstract:
Background: Data on the epidemiology of  tuberculosis and its treatment outcomes were incomplete in the study area and this 
study was done to fill this gap.
Methods: Institution based cross sectional study was conducted from January 2011 to December 2014. A total of  949 TB pa-
tients who were on treatment in North Eastern Ethiopia, Eastern Amhara region were included. Data was analyzed using SPSS 
version 20. Frequency, percentages and means were used to present data. To assess the associations of  treatment outcomes with 
sex, age, type of  TB and human immunodeficiency virus (HIV), logistic regression was used.
Results: The proportion of  smear positive and negative pulmonary TB, and extra pulmonary TB were 187/949 (19.7%), 
322/949 (33.9%) and 440/949 (46.4%), respectively. Treatment success rate was 853/949 (89.9%). Smear positive pulmonary TB 
and TB/HIV co-infections were significantly associated with unsuccessful treatment outcome, P≤ 0.002.
Conclusion: Extra pulmonary TB was the most prevalent types of  TB followed by smear negative pulmonary TB. Treatment 
success rate was above the WHO target of  85%. The causes for the high proportion of  smear negative PTB and EPTB should 
be further investigated. Special emphasis should be put on smear positive PTB patients and TB/HIV co-infected patients to 
decrease unsuccessful treatment outcome and TB transmissions.
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Background
Tuberculosis (TB) is a disease of  centuries. It killed more 
persons than any other infectious diseases1. Tuberculosis 
is a disease of  poverty and mainly affects poor countries. 
A person with TB loses, on average, 20-30% of  annual 
household income due to illness2.
Acid fast bacilli (AFB) microscopy with spot-morning–
spot sputum sample collection strategy was the recom-
mended technique for the diagnosis and follow-up of  
pulmonary TB (PTB) patients in the Directly Observed 
Treatment short course (DOTS) program3-5. Effective 
treatment of  TB started in 1946, with the introduction 
of  streptomycin (SM). The main problem with current 
chemotherapy is too long duration of  treatment regimen 
thus allowing opportunities for interruptions in drug tak-
ing that may lead to the emergence of  drug resistance6.
Globally, the rate of  treatment success among new smear-
positive PTB who were treated in the 2012 cohort was 
86%. Treatment success rate was higher among smear 
positive PTB than smear negative PTB7.  In Ethiopia in 
the same year, TB treatment success rate among new TB 
cases was 91%5. However; it is unknown among retreated 
cases5.
There was no data about TB treatment outcome in the 
study area in particular. In addition, aggregate national 
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data might not reflect the real TB profile and treatment 
outcomes due to subtle socioeconomic, geographic and 
methodological variations. Thus, studies like this might 
show the appropriate proportion of  mean treatment 
outcome and types of  TB in the specific area. Thus, this 
study was done to determine the profile and treatment 
outcome of  TB patients in Amhara National Regional 




Study setting, period and population
Institution based cross-sectional study was conducted on 
patients diagnosed and treated over the period of  Janu-
ary 2011 to December 2014 in Kobo, Robit and Gobiye 
health centers. These health centers found in eastern Am-
hara region in north wollo zone, 552km away from Ad-
dis Ababa. The woredas are part of  a mid-altitude area 
which lies between the Ethiopian Highlands to the west 
and the Afar depression to the east. Currently, there are 8 
additional health centers in the studied area that provide 
TB diagnosis and treatment. However, these health cen-
ters were newly opened and had incomplete registration 
system to be included in the study.
Tuberculosis diagnosis and treatment strategy
The pulmonary TB diagnosis and treatment was based on 
the stop TB strategy. That is, sputum samples were col-
lected using spot-morning-spot strategy and three slides 
were prepared, one from each sample. Slides were pro-
cessed and examined using the standard Ziehl-Neelsen 
(ZN) AFB staining technique8.
Extra pulmonary TB was diagnosed at nearby govern-
ment and private health institutions primarily based on 
clinical data with limited service of  imaging   and patho-
logical examinations. Diagnosis of  TB in children was 
based on clinical and X-ray findings.
For those patients diagnosed with active TB, the stan-
dard TB treatment regimen; 2(RHZE)/4 (RH) and 2S 
(HRZE)/1(HRZE)/5(HR) E were administered for new 
and previously treated TB patients respectively9.
Operational definitions
Health Center: A primary health care unit that serves a 
population of  15,000-25,000 and is comprised of  special-
ized clinics like TB, antiretroviral treatment (ART), ma-
ternal and child health clinics.
Inclusion and exclusion criteria
All TB patients with complete demographic and clinical 
data were included in the study. Whereas, patients with 
unknown types of  TB and treatment outcomes, including 
transferred out were excluded.
Data collection and tools                                                                                      
Demographic and clinical data such as age, sex, type of  
TB, TB treatment outcome, status of  human immunode-
ficiency virus (HIV) infection, co-trimoxazole prophylax-
is (CPT) and antiretroviral treatment (ART) status were 
retrieved from TB registry using data extraction sheets.
Data analysis
Collected data was entered, cleared, and analyzed using 
SPSS statistical software package (IBM Corp. Released 
2011. IBM SPSS Statistics for Windows, Version 20.0. 
Armonk, NY: IBM Corp.). Frequency, percentage, mean 
and standard deviation (SD) were used to present data. 
To assess the associations of  treatment outcome with 
sex, age, type of  TB and HIV status; stepwise logistic 
regression model was used. Variables with a p-value of  
≤0.2  PubMed in bi variate analysis were included in the 
multivariate analysis.Associations were determined using 
odds ratio and 95% confidence interval. A p-value of  < 
0.05 was considered to indicate statistical significance.
Ethics statements
This study was approved by Amhara Regional Health Bu-
reau Institutional Ethical Review Board (IRB) to utilize 
the data. No patient details that may link to the patient 
identity were used and the confidentially was maintained.
 
Results
Demographic epidemiology of  tuberculosis
Among the total of  990 TB patients registered on TB 
notification books, 30 (3%) were transferred out and 11 
(1.1%) were with unknown treatment outcomes. We ex-
cluded these categories of  patients. Thus, data from a to-
tal of  949 TB patients were included for analysis. Of  the 
total included, 528/949 (55.4%) were males. Mean age 
of  participants were 32.8 years with SD of  16.3. More-
over, high proportions of  TB patients; 285/949 (30%) 
and 212/949 (22.3%) were in the age groups of  25-34 
and 15-24 years, respectively [Table 1].
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Table 1: Distribution of demographic characteristics and HIV status among tuberculosis 













    
Sex Female 91 (48.6) 133 (41.3) 197 (44.7) 421 (44.5)   
Male 96 (51.4) 189 (58.7) 243 (55.3) 528 (55.5)   
Age <=14 5 (2.7) 29 (9) 61 (13.9) 95 (10)   
15-24 51 (27.3) 66 (20.5) 95 (21.6) 212 (22.3)   
25-34 70 (37.4) 94 (29.2) 121 (27.5) 285 (30)   
35-44 25 (13.4) 43 (13.3) 53 (12) 121 (12.7)   
45-54 18 (9.6) 44 (13.6) 47 (10.7) 109 (11.5)   
55-64 11 (5.9) 21 (6.5) 38 (8.6) 70 (7.4)   
>=65 7 (3.7) 25 (7.7) 25 (5.7) 57 (6)   
HIV Status Unknown 6 (3.2) 6 (1.8) 6 (1.4) 18 (1.9)   
Positive 65 (34.8) 87 (27) 75 (17) 227 (24)   
Negative 116 (62) 229 (71.1) 35 9(81.6) 704 (74.2)   





Profile of  tuberculosis
The proportion of  smear positive PTB, smear negative 
PTB and EPTB were 187/949 (19.7%), 322/949 (33.9%) 
and 440/949 (46.4%), respectively [Table 1]. There was 
no significant difference on the types of  TB with regard 
to sex and age of  participants. The proportion of  TB/
HIV co-infection was 227/949 (24%). Moreover, TB/
HIV co-infection was twice higher among smear positive 
PTB than EPTB [Table 1].
Tuberculosis treatment outcomes
The overall unsuccessful treatment outcome was 96/949 
(10.1%) wherein failed, died and lost to follow up shared 
at 21/949 (2.2%), 47/949 (5%) and 28/949 (2.9%) re-
spectively. It is found that the proportion of  unsuccess-
ful TB treatment outcome was higher among male and 
older age patients than their counterparts with no statisti-
cal significance. On the other hand, the proportion of  
cured was at 132/949 (13.9%) and treatment completed 
at 721/949 (76%) [Table 2].
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Table 2: Distribution of tuberculosis treatment outcomes by demographic and profile of TB 
patients, Kobo and Raya Kobo Woredas-Ethiopia, 2015. 
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Sex Female 63 
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Furthermore, significant differences were observed on 
treatment outcome between smear positive PTB and 
EPTB, and between HIV positive and HIV negative TB 
patients [Table 3].
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Discussion
This study revealed high proportion of  TB among males 
than females. This agreed with different findings reported 
in Ethiopia and aboard5,10-13. The possible reason might 
be related with, lower rates of  notification of  TB among 
women than men due to low health seeking behavior, lack 
of  financial control and stigma associated with being TB 
positive2. Majority, at 22.3% and 30% of  TB patients were 
in the age groups of  15-24 and 25-34 years respectively. 
This report is also in line with other literatures5,10,14-15 
which indicated that, TB mainly affects the reproductive 
segment of  the population. This might be due to high 
HIV prevalence in these age groups (personal opinion).
The TB profile data showed that high proportions of  TB 
patients were EPTB and smear negative PTB which is 
comparable with other Ethiopian TB profile data16. How-
ever, it is in contrary with reports from outside Ethiopia 
5,14,17-18. Currently, two justifications seems plausible: the 
role of  false positive20/over prescription/ and the zoo-
notic transmission, social and host-pathogen genomic 
factors21. These two justifications are presented as fol-
lows;
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Table 3: Association of unsuccessful treatment outcomes with possible predictors among tuberculosis 
patients, Kobo and Raya Kobo Woreda-Ethiopia, 2015. 
Variables TB treatment outcome Over all P-value 
of binary 
regression  








Sex: 0.89  
Male 54 (56.3) 474 (55.6) 528  - 
Female 42 (43.7) 379 (44.4) 421  
Age: 0.17  
0-14 4 (4.2) 91(10.7) 95  0.3(0.08-1), 0.06 
15-24 21 (21.8) 191 (22.4) 212  0.64(0.2-1.6), 0.35 
25-34 25 (26.0) 260 (30.5) 285  0.4(0.16-1.07), 0.07 
35-44 14 (14.6) 107 (12.5) 121  0.65(0.24-1.7), 0.4 
45-54 13 (13.5) 96 (11.3) 109  0.79(0.3-2.1), 0.66 
55-64 12 (12.5) 58 (6.8) 70  1.3(0.5-3.8), 0.5 
≥65 7  (7.3) 50 (5.9) 57  1 
Types of TB: 0.0001  
PTB+ 35 (36.5) 152 (17.8) 187  2.3(1.3-3.8), 0.02 
PTB- 26 (27.1) 296 (34.7) 322  0.88(0.5-1.5), 0.6 
EPTB 35 (36.4) 405 (47.5) 440  1 
HIV Status: 0.0001  
Unknown 3 (3.1) 15 (1.8) 18  2.6(0.7-9.6), 0.15 
Positive 39 (40.6) 188 (22.0) 227  2.6(1.6-4.27), 0.001 
Negative  54 (56.3) 650 (76.2) 704  1 
Total 96(10.1) 853 (89.9) 949   
The first argument discussed that, most of  EPTB and 
smear negative PTB cases were diagnosed and transferred 
in from private health facilities. However, these facilities 
might not have well organized facilities and expertise to 
diagnose EPTB and smear negative PTB cases. This is 
in line with studies by Iwnetu et al.  and Ehlers et al . 
According to these studies, up to 15% of  all EPTB and 
97.3% smear negative PTB cases were diagnosed wrong-
ly19-20.  Furthermore, clinicians might abused the low sen-
sitivity of  ZN and low specificity of  pathological tests 
and might rushed to diagnose presumptive TB cases as 
confirmed smear negative PTB/EPTB (expert opinion)
The other justification goes in line with Berg et al, study 
justified that regular and direct contact with live animals, 
was a significant risk factor for EPTB21. These factors also 
seem likely, because, people in the study area are known 
live stock keepers and due to their local tradition, most of  
their domestic animals shared human shelter. Moreover, 
these people regularly use raw meat and milk. Moreover, 
the high smear negative PTB might be due to difference 
in the immunological and nutritional status of  Ethiopian 
with other counties (unpublished report). However, to 
identify the real cause of  such high prevalence report in 
Ethiopia, it needs further comparative ecological and co-
hort study.
In the present study, the proportion of  TB/HIV co-in-
fection was at 227/949 (24%), much higher than WHO 
report of  the year 201522. Moreover, TB/HIV co-infec-
tion was twice higher among smears positive PTB than 
EPTB which is in contrary with a literature23. This can 
be explained by tailoring to Ethiopian situation.  If  the 
reports of  Iwunetu et al. and Ehlers et al., mentioned 
above, considered as a possible cause for high rate of  
EPTB and smear negative PTB in Ethiopia, this would 
also dilute the TB/HIV co-infection rate among EPTB 
and smear negative PTB patients. 
The odd of  having unsuccessful treatment outcome was 
2.3 times higher among smear positive PTB than EPTB 
patients (AOR: 2.3; 95% CI: 1.3-3.8; P: 0.02). This might 
be due to higher HIV prevalence, (34.8%) among smear 
positive PTB than smear negative PTB (27%) and EPTB 
(17%) [Table 1]. Similar finding was reported from Addis 
Ababa24.
The odds of  having unsuccessful TB treatment outcome 
was 2.6 times higher among TB/HIV co-infected than 
HIV negative TB patients (AOR: 2.6; 95% CI: 1.6-4.27; 
p< 0.0001) (Table 3). This might be due to low level of  
immunity and drug mal-absorption25. This finding was in 
line with a study from Addis Ababa, Eastern Ethiopia, 
Benin and Malawi15,24,26,-27. Furthermore, the proportion 
of  unsuccessful treatment outcome was higher among 
TB/HIV co-infected people with no history of  CPT and 
ART than those on CPT and ART [data not shown]. Ad-
ministration of  ART is recommended during TB ther-
apy regardless of  the CD4 cell count,28 because ART is 
associated with reduction in mortality and HIV disease 
progression29-32. Moreover, all HIV-infected patients with 
active TB should receive CPT30,22
Limitation of  the study
The recorded data lack detail clinical profile like CD4 
count and other comorbidies. On top of  this, due to the 
inherent limitation of  the study design, the study couldn’t 
show any cause effect relation between significantly as-
sociated variables.
Conclusions and recommendations
The proportion of  smear negative PTB and EPTB were 
higher than smear positive PTB cases. Plus, the overall 
TB treatment success rate was above the WHO target of  
>85%. Moreover, smear positive PTB and TB/HIV co-
infections were significantly associated with unsuccessful 
TB treatment outcomes. Thus, we would like to forward 
the following recommendations; (1) the causes for the 
high proportion of  smear negative PTB and EPTB cases 
should be further investigated. (2) The ART and CPT 
coverage must reach 100% to TB/HIV co-infected pa-
tients so that their unsuccessful treatment outcome rate 
would be improved. (3) Especially emphasis should be 
paid to smear positive PTB patients to decrease unsuc-
cessful treatment outcome and decrease transmissions.
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